89 results
A pilot feasibility study (n=5) will be performed to evaluate the feasibility (logistics, timing) and safety of administering autologous tumor infiltrating lymphocytes (TIL) generated at the NKI-AVL infused in conjunction with systemic high-dose…
The primary objective of the study is:- to establish the safety and feasibility of infusion of escalating doses of autologous ASC in end-stage renal disease patients. Secondary objectives are:- to determine the effect of ASC infusion on kidney…
The primary objective of the study is to evaluate the efficacy of intralesional administration of eASCs (CX-401) when added to standard surgical care and drainage for the treatment of complex perianal fistulas in patients with Crohn*s disease (CD).
> Primary Objective:This is a pilot study, aiming at the clinical evaluation with respect to safety and feasibility of a one-step surgical procedure for maxillary sinus floor augmentation for the placement of dental implants, using a ceramic…
The primary goal is to show the capability of monocyte-derived DC after RNA electroporation for melanoma antigens to induce an immune response.The secondary objective is to show clinical response.
ObjectiveEvaluation of the application of cultured autologous keratinocytes in combination with a meshed split skin autograft to improve burn wound healing
The primary goal is to show the capability of monocyte-derived DC after RNA electroporation for multiple antigens to induce an immune response. The secondary objective is to show clinical response.
To determine the efficacy and safety of PREOB®, a proprietary population of autologous bone-forming cells, in the treatment of early stage non-traumatic osteonecrosis of the femoral head.
To investigate feasibility, safety and toxicity as well as immune-response of an allogeneic tumor cell lysate (PheraLys) loaded onto autologous dendritic cells (MesoPher) in resected pancreatic cancer patients who received adjuvant standard of care…
The overall study objective is to evaluate the safety and efficacy of NiCord®: single ex-vivo expanded cord blood unit transplantation in patients with hematological malignancies following myeloablative therapy.
To evaluate the safety and toxicity of ACT and low-dose IFN-alpha plus nivolumab according to CTCAE 4.0 criteria. Toxicity grade 3 or less and SAE related to treatment but that do not result in treatment termination are considered acceptable for…
The main objective is to objectify if the injection of SVF influences the pain of the TMJ during movement. Secondary objectives are pain during rest, maximum mouth opening, and function evaluation.
Primary Objective* To determine the OS of subjects treated with ICT-107 and standard of care (RT and TMZ) vs. placebo control and standard of care (RT and TMZ) :Secondary Objectives* To determine the OS of subjects with unmethylated MGMT tumors…
The main objective is assessment of safety and feasibility of intravenous administration of autologous, in vitro expanded, mesenchymal stem cells in patients with pulmonary arterial hypertension due to systemic sclerosis. The secondary objective is…
To determine the efficacy and the safety of PREOB®, a proprietary population of autologous bone-forming cells, in the treatment of non-infected hypotrophic non-union fractures of long bones.
The study will evaluate the injection of AMDC for Urinary Sphincter Repair (USR) compared to a placebo dose, with the hypothesis that one or two treatments of AMDC is statistically superior to placebo at 12 months following the initial treatment.
Primary ObjectiveTo demonstrate that the effectiveness of the NOVOCART® 3D plus autologouschondrocyte transplantation system is superior to microfracture for the treatment ofarticular cartilage defects of the knee by demonstrating superiority of the…
Determine the safety and efficacy of Tiscover compared to AS210 (acellular donor dermis, construct Tiscover is cultured on) for the treatment of chronic, therapy resistant (arterio-) veneus leg/foot ulcers in an out patient setting.
To define and evaluate OCT stent guidance parameters through prospective data collection in PCI procedures of de novo lesions.
1. The primary objectives of this phase I/II clinical trial is to demonstrate feasibility and evaluate the safety and toxicity of ACT plus vaccination according to CTCAE 4.0 criteria.2. Secondary objectives include the evaluation of the clinical…